Rigel Pharmaceuticals INC Form 4 insider transactions

Rigel Pharmaceuticals Inc. director Michael Patrick Miller was granted 12,000 stock options with an exercise price of $34.86, vesting monthly starting February 1, 2026.

Rigel Pharmaceuticals' EVP & CFO, Dean L. Schorno, exercised multiple employee stock options on December 22, 2025, increasing his direct beneficial ownership of common stock.

Rigel Pharmaceuticals' EVP & CFO, Dean L. Schorno, has vested 7,394 performance-based stock options after a key metric was met on September 15, 2025.

Rigel Pharmaceuticals' EVP, Chief Commercial Officer, David A. Santos, had a performance-based stock option for 7,394 shares vest on September 15, 2025, following the satisfaction of a performance metric.

Rigel Pharmaceuticals' EVP, Chief Medical Officer, Lisa Rojkjaer, had a performance-based stock option for 7,394 shares vest on September 15, 2025, after meeting the required metric.

Raymond J. Furey, EVP, GC, CCO & Corp Sec of Rigel Pharmaceuticals, reported the vesting of 7,394 performance-based stock options with an exercise price of $22.49.

Rigel Pharmaceuticals CEO Raul R. Rodriguez's performance-based stock option for 31,700 shares, granted on January 29, 2025, fully vested on September 15, 2025, upon meeting its performance metric.

Rigel Pharmaceuticals Director Jane Wasman has acquired 2,500 shares of common stock through RSU vesting and 3,000 stock options, reflecting ongoing equity compensation and alignment with shareholder interests.

Rigel Pharmaceuticals Inc. Director Kamil Ali-Jackson was granted 2,500 Restricted Stock Units and 3,000 stock options, aligning her interests with shareholders.

Rigel Pharmaceuticals Inc. Director Walter H. Moos was granted 2,500 restricted stock units and options to purchase 3,000 shares of common stock on May 23, 2025, as part of his compensation.

Rigel Pharmaceuticals Inc. Director Anthony Gregg Lapointe reported the acquisition of 2,500 shares of common stock through Restricted Stock Units and 3,000 stock options, reflecting recent equity compensation.

Rigel Pharmaceuticals Inc. Director Alison L. Hannah was granted 2,500 Restricted Stock Units and 3,000 stock options as part of her compensation, aligning her interests with shareholders.

Rigel Pharmaceuticals Director Mark W. Frohlich has reported the acquisition of 1,250 shares of common stock through a Restricted Stock Unit award and 1,500 stock options, aligning his interests with the company's performance.

Dean L. Schorno, EVP & CFO of Rigel Pharmaceuticals, reports the acquisition of stock options after performance-based conditions were satisfied on March 17, 2025.

David A. Santos, EVP and Chief Commercial Officer of Rigel Pharmaceuticals, reports the acquisition of stock options after performance-based conditions were satisfied.

Lisa Rojkjaer, EVP and Chief Medical Officer of Rigel Pharmaceuticals, reports the grant of a stock option for 9,375 shares after a performance metric was met.

Rigel Pharmaceuticals CEO Raul Rodriguez exercised stock options after performance-based conditions were met, acquiring rights to purchase shares of common stock.

Raymond Furey, EVP, GC, CCO & Corp Sec of Rigel Pharmaceuticals, reports the acquisition of stock options after performance-based conditions were met on March 17, 2025.

Director Mark W. Frohlich acquired 12,000 stock options in Rigel Pharmaceuticals, Inc. on March 6, 2025, according to a Form 4 filing.

Dean L. Schorno, EVP & CFO of Rigel Pharmaceuticals, sold shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

David A. Santos, EVP, Chief Commercial Officer of Rigel Pharmaceuticals, sold shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Rigel Pharmaceuticals CEO Raul Rodriguez sold shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Raymond Furey, EVP, GC, CCO & Corp Sec of Rigel Pharmaceuticals, sold shares of common stock to cover tax withholding obligations related to vesting Restricted Stock Units.

Lisa Rojkjaer, EVP and Chief Medical Officer at Rigel Pharmaceuticals, acquired shares and stock options on January 29, 2025, as part of her compensation.

Rigel Pharmaceuticals CEO, Raul R. Rodriguez, acquired 42,300 shares of common stock and 63,400 stock options on January 29, 2025.

Dean L. Schorno, EVP & Chief Financial Officer of Rigel Pharmaceuticals, acquired shares and stock options on January 29, 2025, as part of a vesting schedule.

David A. Santos, EVP and Chief Commercial Officer at Rigel Pharmaceuticals, acquired shares and stock options on January 29, 2025, according to a recent SEC filing.

Raymond J. Furey, an executive at Rigel Pharmaceuticals, acquired shares and stock options as part of a compensation package.

Rigel Pharmaceuticals CEO, Raul R. Rodriguez, exercised stock options and sold shares on January 24, 2025, according to a recent SEC filing.

Rigel Pharmaceuticals' EVP, Chief Commercial Officer, David A. Santos, exercised stock options for 8,000 shares after a performance-based condition was met.